Success story of Aurobindo Pharma

In the period between 1988-89, the company only manufactured penicillin. They have since then expanded into antibiotics, anti-allergic, antiretrovirals, cardiovascular, central nervous system and gastroenterological categories.

In 2018, an Indian pharmacy became the second-largest generic pharmaceutical company in the world’s toughest market, the United States of America. We are talking about an Indian pharma company - Aurobindo Pharma. Not only did this company rival global giant Mylan it also gave severe competition to the world’s largest generic drug manufacturer -  Teva. Their marketing partners are AstraZeneca and Pfizer. The company’s founder. Ramprasad Reddy was one of the few drug manufactures that were invited to speak at the United Nations in 2006.

The journey of Aurobindo Pharma and its founder Ramprasad Reddy is truly inspiring. After his postgraduation in Commerce from Venkateshwara University, he along with friend Nityananda Reddy started trading. Nityananda Reddy with his education in Chemistry and work experience at Tini Pharma helped Ramprasad a lot. The small chemical traders soon turned their venture into a multinational pharmacy company worth billions of dollars. 

The company was founded in 1986 in Andra Pradesh. It was later converted into a Public Limited Company in 1992. In the period between 1988-89, the company only manufactured penicillin. They have since then expanded into antibiotics, anti-allergic, antiretrovirals, cardiovascular, central nervous system and gastroenterological categories. In 2014 for $41 million, Aurobindo purchased Actavis’s operation in seven European countries. In 2017, they acquired Portugal’s Generis for a whopping €135 million. They also acquired four biosimilar products from Swiss-based TL Biopharmaceuticals AG.

They are the largest manufacturer of Ampicillin and Cloxacillin in India. In 2018, 90% of the company’s revenue came from exports. Today, 70% of its revenue comes from exports that occur in 125 countries. Currently, an estimated 14% comes from generic injectables and oncology injectables. For the former Aurobindo has an estimated $400 million and for the latter $95 million. In FY21, generic injectables and the ophthalmic section alone reported Rs 9.3 billion in revenues. This was 5.9% of their overall revenue. 

Aurobindo Pharma and its founder Ramprasad Reddy’s tale is an inspiration to many. Coming from a humble background he has made for himself a fortune. Reddy, despite his language deficiencies, truly holds power in any negotiation. He has a steadfast decision making prowess and a discipline of keeping consistent prices. These traits have helped Reddy transform its small venture into a global giant in pharmaceuticals. 

Tags : #AurobindoPharma #RamprasadReddy #NityanandaReddy #AstraZeneca #Pfizer #multinationalpharmacy #pharmaceuticals #success #medicircle #smitakumar

About the Author


Priyal Shah

Priyal Shah is a graduate of Media from Mithibai College, Mumbai. She is a writer, researcher and avid reader.

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Parental tips for keeping teens safe onlineFebruary 08, 2023
The Symptoms and Causes of Anorexia NervosaFebruary 08, 2023
Pervez Musharraf President of Pakistan died of Amyloidosis, a rare diseaseFebruary 07, 2023
National AIDS Control Program – Importance of knowing HIV statusFebruary 06, 2023
FGM : Let's End the practice that hurts girls and womenFebruary 06, 2023
World Cancer Day - Most prominent cancers of IndiaFebruary 04, 2023
World Cancer Day - Never Give up the HopeFebruary 04, 2023
Salt - Effects of Consuming too much SaltFebruary 03, 2023
India’s mission of eliminating dog-mediated rabies by 2030February 03, 2023
Climate change and healthFebruary 02, 2023
Rheumatoid Arthritis Awareness Day: Let's Create AwarenessFebruary 02, 2023
Importance of early diagnosis and cancer screeningFebruary 01, 2023
Union Budget 2023-2024: What's for Healthcare?February 01, 2023
Nourish You has raised $2million to Invest in R&D and Strengthen its Market Presence.February 01, 2023
Enzene Biosciences has raised $50million to expand in its core market of India and US.January 31, 2023
Enzene Biosciences has raised $50million to expand in its core market of India and US.January 31, 2023
World Leprosy Day 2023 – Act now, End LeprosyJanuary 30, 2023
The Warrior Expedition 32/26: A Mission to Encourage Youths to join Indian ForcesJanuary 30, 2023
Mental health – What’s normal and what’s abnormalJanuary 30, 2023
Big Data in Healthcare and Its BenefitsJanuary 27, 2023